

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

June 17, 2011

<u>Via Email</u> Punit Dhillon President & Chief Executive Officer OncoSec Medical Incorporated 4690 Executive Drive, Suite 250 San Diego, CA 92121

> Re: OncoSec Medical Incorporated Item 4.01 Form 8-K Filed June 2, 2011 Am. No. 1 to Item 4.01 Form 8-K Filed June 10, 2011 File No. 0-54318

Dear Mr. Dhillon:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Jennifer Thompson

Jennifer Thompson Accounting Branch Chief